SCHEMBL17739495

SCHEMBL17739495

CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6ccnc6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 20/20 0.90
▸ MAPT P10636 3/20 0.81
▸ MAPK1 P28482 3/20 0.81
▸ MEN1 O00255 2/20 0.81
▸ ABCB11 O95342 2/20 0.81
▸ LMNA P02545 2/20 0.81
▸ ABCB1 P08183 2/20 0.81
▸ KMT2A Q03164 2/20 0.81
▸ HIF1A Q16665 2/20 0.81
▸ CYP51A1 Q16850 2/20 0.81
▸ ABCG2 Q9UNQ0 2/20 0.81
▸ CYP8B1 Q9UNU6 2/20 0.81
▸ FYN P06241 1/20 0.81
▸ CXCR1 P25024 1/20 0.81
▸ TACR1 P25103 1/20 0.81
▸ AVPR2 P30518 1/20 0.81
▸ CCR4 P51679 1/20 0.81
▸ PDE4D Q08499 1/20 0.81
▸ CYP21A2 P08686 6/20 0.72
▸ CYP19A1 P11511 6/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20710056 1.00 CYP3A4 (0.90) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL31330298 1.00 CYP3A4 (0.90) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL20710020 1.00 CYP3A4 (0.90) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL31330271 1.00 CYP3A4 (0.90) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL17739444 1.00 CYP3A4 (0.90) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL20710079 1.00 CYP3A4 (0.90) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL11078787 0.95 CYP3A4 (0.81) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL11078785 0.95 CYP3A4 (0.81) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL24335660 0.95 CYP3A4 (1.00) CYP3A4MAPTMAPK1MEN1ABCB11
SCHEMBL20710042 0.95 CYP3A4 (1.00) CYP3A4MAPTMAPK1MEN1ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3626242-A1 ITRACONAZOLE ANALOGS AS INHIBITORS OF FIBROSIS The Scripps Research Institute (US) 2020-03-25 — — EP disclosed
US-20170217943-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2017-08-03 — — US disclosed
US-20170217943-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2017-08-03 — — US disclosed
US-20160130258-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2016-05-12 — — US disclosed
US-20160130258-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2016-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130258-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS MMP1, COL2A1, MMP8 CYP3A4 4660/4885MAPT 4142/4885MAPK1 1794/4885
US-20170217943-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS MMP1, COL2A1, MMP8 CYP3A4 4660/4885MAPT 4142/4885MAPK1 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback